Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer (original) (raw)
AMH as an ovarian function predictor in premenopausal female breast cancer patients receiving chemotherapy is effective only for those over 35 years old
sixuan Liu
2020
View PDFchevron_right
Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review
maeliss peigne
Reproductive Biology and Endocrinology, 2014
View PDFchevron_right
Can Anti-Müllerian Hormone Be a Reliable Biomarker for Assessing Ovarian Function in Women Postchemotherapy?
sixuan Liu
Cancer Management and Research, 2020
View PDFchevron_right
A highly-sensitive anti-Müllerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer
Forbes Howie
European journal of cancer (Oxford, England : 1990), 2014
View PDFchevron_right
Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy
Yasmin Gosiengfiao, Maureen Prewitt
Fertility and Sterility, 2013
View PDFchevron_right
Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay
Didier Dewailly
Fertility and Sterility, 2014
View PDFchevron_right
Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in …
Martine Berliere
intechopen.com
View PDFchevron_right
Assessing The Impact Of Cancer Therapies On Ovarian Reserve
jill ginsberg
Fertility and Sterility
View PDFchevron_right
Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer
Kathryn Ruddy
Fertility and Sterility, 2010
View PDFchevron_right
Ovarian Reserve after Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis
Ilaria Romito
Journal of Personalized Medicine, 2021
View PDFchevron_right
Anti-mullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies
Frank Jong
Human Reproduction, 2008
View PDFchevron_right
Anti-müllerian hormone compared with other ovarian markers after childhood cancer treatment
Ingrid Øra
Acta Oncologica, 2018
View PDFchevron_right
Predictors of ovarian reserve in young women with breast cancer
Ashlesha Patel
British Journal of Cancer, 2007
View PDFchevron_right
Impact of cancer therapies on ovarian reserve
Maureen Prewitt
Fertility and Sterility, 2012
View PDFchevron_right
Acute onset of ovarian dysfunction in young females after start of cancer treatment
Ingrid Øra
Pediatric Blood & Cancer, 2013
View PDFchevron_right
Anti-Müllerian Hormone and Antral Follicle Count Reveal a Late Impair- Ment of Ovarian Reserve in Patients Undergone Low Gonadotoxic Regimens for Haematological Malignancies
Alessio Perandini
2013
View PDFchevron_right
Avaliação da reserva ovariana em mulheres com câncer de mama submetidas à quimioterapia
Ângela Davila
2013
View PDFchevron_right
Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea
Emanuel Trabuco
JNCI: Journal of the National Cancer Institute, 2020
View PDFchevron_right
Patients with cancer at the margins of reproductive age had reduced levels of anti-Müllerian hormone compared with patients experiencing infertility
Edgar Mocanu
International Journal of Gynecology & Obstetrics, 2016
View PDFchevron_right
A Pilot Study of Predictive Markers of Chemotherapy-Related Amenorrhea Among Premenopausal Women with Early Stage Breast Cancer
Sue Unruhe, Gretchen Kimmick, Bercedis Peterson
Cancer Investigation, 2008
View PDFchevron_right
Predicting chemotherapy‐induced menopause using baseline and post‐chemotherapy anti‐Müllerian hormone levels: Results of a pilot study
Shawgi Sukumaran
Cancer Reports
View PDFchevron_right
Anti-Müllerian Hormone as a Sensitive Marker of Ovarian Function in Young Cancer Survivors
Beata Zelazowska-rutkowska
International Journal of Endocrinology, 2013
View PDFchevron_right
Anti-Müllerian hormone screening to assess ovarian reserve among female survivors of childhood cancer
SAMEERA AHMED
Journal of Cancer Survivorship, 2014
View PDFchevron_right
Antral Follicles Count and Anti-Müllerian Hormone Levels after Gonadotoxic Chemotherapy in Patients with Breast Cancer: Cohort Study
Helena Corleta
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2017
View PDFchevron_right
Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age
Anders Juul
Fertility and Sterility, 2010
View PDFchevron_right
Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments
Teresa Almeida Santos
Journal of Ovarian Research
View PDFchevron_right
The physiology and clinical utility of anti-Mullerian hormone in women
Didier Dewailly, Tom Kelsey
Human Reproduction Update, 2014
View PDFchevron_right
Anti-Mullerian Hormone and Antral Follicle Count Reveal a Late Impairment of Ovarian Reserve in Patients Undergoing Low-Gonadotoxic Regimens for Hematological Malignancies
Alessio Perandini
The Oncologist, 2013
View PDFchevron_right
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients
Piero Fregatti
Journal of the National Cancer Institute, 2021
View PDFchevron_right
Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception
Mary Sammel
Fertility and sterility, 2014
View PDFchevron_right
Decreased serum anti-Mullerian hormone levels in girls with newly diagnosed cancer
Saskia Pluijm
Human Reproduction, 2014
View PDFchevron_right